Synthetic Dual-action Vaccines

U.S. and Canadian researchers have developed a technique to produce fully synthetic vaccines and have mouse data showing the prevention of candidiasis, a range of oral, vaginal and systemic yeast infections.1 Although a candidiasis vaccine would have limited commercial prospects, Wellstat Therapeutics Inc. says the data provide proof of concept for the technology. The company has in-licensed relevant facets of the synthetic vaccine technology and has used it to move vaccines into preclinical development for other pathogens.

Although the next academic step is to test scaled-up versions of the researchers' vaccine, one question for drug developers will be whether the technique can be applied to more complex pathogens.

The study, published in the Proceedings of the

Read the full 1144 word article

How to gain access

Continue reading with a
two-week free trial.